share_log

Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target

Moomoo 24/7 ·  Mar 27 07:41

Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment